{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:32:35Z","timestamp":1777008755404,"version":"3.51.4"},"reference-count":45,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":3331,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,1]]},"abstract":"<jats:sec>\n                  <jats:title\/>\n                  <jats:p>Advanced glycation end products (AGEs) are important mediators of diabetic nephropathy that act through the receptor for AGEs (RAGE), as well as other mechanisms, to promote renal inflammation and glomerulosclerosis. The relative contribution of RAGE-dependent and RAGE-independent signaling pathways has not been previously studied in vivo. In this study, diabetic RAGE apoE double-knockout (KO) mice with streptozotocin-induced diabetes were treated with the AGE inhibitor, alagebrium (1 mg\/kg\/day), or the ACE inhibitor, quinapril (30 mg\/kg\/day), for 20 weeks, and renal parameters were assessed. RAGE deletion attenuated mesangial expansion, glomerular matrix accumulation, and renal oxidative stress associated with 20 weeks of diabetes. By contrast, inflammation and AGE accumulation associated with diabetes was not prevented. However, treatment with alagebrium in diabetic RAGE apoE KO mice reduced renal AGE levels and further reduced glomerular matrix accumulation. In addition, even in the absence of RAGE expression, alagebrium attenuated cortical inflammation, as denoted by the reduced expression of monocyte chemoattractant protein-1, intracellular adhesion molecule-1, and the macrophage marker cluster of differentiation molecule 11b. These novel findings confirm the presence of important RAGE-independent as well as RAGE-dependent signaling pathways that may be activated in the kidney by AGEs. This has important implications for the design of optimal therapeutic strategies for the prevention of diabetic nephropathy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/db11-1546","type":"journal-article","created":{"date-parts":[[2012,6,15]],"date-time":"2012-06-15T05:41:57Z","timestamp":1339738917000},"page":"2105-2113","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":59,"title":["Alagebrium Reduces Glomerular Fibrogenesis and Inflammation Beyond Preventing RAGE Activation in Diabetic Apolipoprotein E Knockout Mice"],"prefix":"10.2337","volume":"61","author":[{"given":"Anna M.D.","family":"Watson","sequence":"first","affiliation":[{"name":"Diabetes Complications Division, Diabetes and Kidney Disease, Baker IDI Heart and Diabetes Research Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen P.","family":"Gray","sequence":"additional","affiliation":[{"name":"Diabetes Complications Division, Diabetes and Kidney Disease, Baker IDI Heart and Diabetes Research Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Jiaze","sequence":"additional","affiliation":[{"name":"Diabetes Complications Division, Diabetes and Kidney Disease, Baker IDI Heart and Diabetes Research Institute, Melbourne, Victoria, Australia"},{"name":"Department of Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aino","family":"Soro-Paavonen","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedict","family":"Wong","sequence":"additional","affiliation":[{"name":"Diabetes Complications Division, Diabetes and Kidney Disease, Baker IDI Heart and Diabetes Research Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Diabetes Complications Division, Diabetes and Kidney Disease, Baker IDI Heart and Diabetes Research Institute, Melbourne, Victoria, Australia"},{"name":"Department of Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Bierhaus","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raelene","family":"Pickering","sequence":"additional","affiliation":[{"name":"Diabetes Complications Division, Diabetes and Kidney Disease, Baker IDI Heart and Diabetes Research Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Tikellis","sequence":"additional","affiliation":[{"name":"Diabetes Complications Division, Diabetes and Kidney Disease, Baker IDI Heart and Diabetes Research Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despina","family":"Tsorotes","sequence":"additional","affiliation":[{"name":"Diabetes Complications Division, Diabetes and Kidney Disease, Baker IDI Heart and Diabetes Research Institute, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merlin C.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Diabetes Complications Division, Diabetes and Kidney Disease, Baker IDI Heart and Diabetes Research Institute, Melbourne, Victoria, Australia"},{"name":"Department of Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin A.M.","family":"Jandeleit-Dahm","sequence":"additional","affiliation":[{"name":"Diabetes Complications Division, Diabetes and Kidney Disease, Baker IDI Heart and Diabetes Research Institute, Melbourne, Victoria, Australia"},{"name":"Department of Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2012,7,17]]},"reference":[{"key":"2022031223061444400_B1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000324945","article-title":"Advanced glycation end products","volume":"170","author":"Thomas","year":"2011","journal-title":"Contrib Nephrol"},{"key":"2022031223061444400_B2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000095786","article-title":"Prevention and reversal of diabetic nephropathy in db\/db mice treated with alagebrium (ALT-711)","volume":"26","author":"Peppa","year":"2006","journal-title":"Am J Nephrol"},{"key":"2022031223061444400_B3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd2476","article-title":"Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials","volume":"8","author":"Calcutt","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"2022031223061444400_B4","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1097\/01.ASN.0000133025.23732.46","article-title":"Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products","volume":"15","author":"Lassila","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2022031223061444400_B5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000108104","article-title":"Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy","volume":"27","author":"Williams","year":"2007","journal-title":"Am J Nephrol"},{"key":"2022031223061444400_B6","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.2337\/diabetes.52.8.2110","article-title":"Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine","volume":"52","author":"Babaei-Jadidi","year":"2003","journal-title":"Diabetes"},{"key":"2022031223061444400_B7","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1096\/fj.02-1102fje","article-title":"The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes","volume":"17","author":"Forbes","year":"2003","journal-title":"FASEB J"},{"key":"2022031223061444400_B8","doi-asserted-by":"crossref","first-page":"11704","DOI":"10.1073\/pnas.91.24.11704","article-title":"Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats","volume":"91","author":"Vlassara","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022031223061444400_B9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrneph.2010.54","article-title":"RAGE and the pathogenesis of chronic kidney disease","volume":"6","author":"D\u2019Agati","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"2022031223061444400_B10","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1007\/s00125-010-1837-2","article-title":"Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor","volume":"53","author":"Sourris","year":"2010","journal-title":"Diabetologia"},{"key":"2022031223061444400_B11","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.2337\/db09-1766","article-title":"Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse","volume":"59","author":"Reiniger","year":"2010","journal-title":"Diabetes"},{"key":"2022031223061444400_B12","doi-asserted-by":"crossref","first-page":"F763","DOI":"10.1152\/ajprenal.00591.2009","article-title":"Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy","volume":"298","author":"Tan","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031223061444400_B13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1172\/JCI11771","article-title":"Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice","volume":"108","author":"Yamamoto","year":"2001","journal-title":"J Clin Invest"},{"key":"2022031223061444400_B14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0002-9440(10)63909-0","article-title":"RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy","volume":"162","author":"Wendt","year":"2003","journal-title":"Am J Pathol"},{"key":"2022031223061444400_B15","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.2337\/db07-1808","article-title":"Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes","volume":"57","author":"Soro-Paavonen","year":"2008","journal-title":"Diabetes"},{"key":"2022031223061444400_B16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00125-009-1540-3","article-title":"The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice","volume":"53","author":"Watson","year":"2010","journal-title":"Diabetologia"},{"key":"2022031223061444400_B17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1161\/01.HYP.25.5.1111","article-title":"A noninvasive computerized tail-cuff system for measuring blood pressure in mice","volume":"25","author":"Krege","year":"1995","journal-title":"Hypertension"},{"key":"2022031223061444400_B18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11892-004-0053-1","article-title":"Use of genetic mouse models in the study of diabetic nephropathy","volume":"4","author":"Allen","year":"2004","journal-title":"Curr Diab Rep"},{"key":"2022031223061444400_B19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00125-010-2000-9","article-title":"Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice","volume":"54","author":"Watson","year":"2011","journal-title":"Diabetologia"},{"key":"2022031223061444400_B20","doi-asserted-by":"crossref","first-page":"F528","DOI":"10.1152\/ajprenal.00127.2010","article-title":"The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse","volume":"299","author":"Giunti","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031223061444400_B21","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.2337\/db10-0552","article-title":"Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function","volume":"59","author":"Miller","year":"2010","journal-title":"Diabetes"},{"key":"2022031223061444400_B22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.RES.0000065620.39919.20","article-title":"A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes","volume":"92","author":"Candido","year":"2003","journal-title":"Circ Res"},{"key":"2022031223061444400_B23","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.2337\/diabetes.51.11.3274","article-title":"Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy","volume":"51","author":"Forbes","year":"2002","journal-title":"Diabetes"},{"key":"2022031223061444400_B24","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1172\/JCI200418704","article-title":"Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response","volume":"113","author":"Liliensiek","year":"2004","journal-title":"J Clin Invest"},{"key":"2022031223061444400_B25","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.4049\/jimmunol.0902517","article-title":"Advanced glycation end products inhibit both infection and transmission in trans of HIV-1 from monocyte-derived dendritic cells to autologous T cells","volume":"186","author":"Nasreddine","year":"2011","journal-title":"J Immunol"},{"key":"2022031223061444400_B26","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1073\/pnas.120055097","article-title":"Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db\/db diabetic mice","volume":"97","author":"Ziyadeh","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022031223061444400_B27","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.2337\/diabetes.53.12.3248","article-title":"Development of late-stage diabetic nephropathy in OVE26 diabetic mice","volume":"53","author":"Zheng","year":"2004","journal-title":"Diabetes"},{"key":"2022031223061444400_B28","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.2337\/db06-0221","article-title":"RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin","volume":"55","author":"Myint","year":"2006","journal-title":"Diabetes"},{"key":"2022031223061444400_B29","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1097\/01.ASN.0000077402.95720.B4","article-title":"Role of galectin-3 in diabetic nephropathy","volume":"14","author":"Iacobini","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2022031223061444400_B30","doi-asserted-by":"crossref","first-page":"11767","DOI":"10.1073\/pnas.0401588101","article-title":"Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells","volume":"101","author":"Lu","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022031223061444400_B31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s001250051591","article-title":"Advanced glycation end-products: a review","volume":"44","author":"Singh","year":"2001","journal-title":"Diabetologia"},{"key":"2022031223061444400_B32","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/01.mjt.0000178769.52610.69","article-title":"Advanced glycation end products and diabetic nephropathy","volume":"12","author":"Thomas","year":"2005","journal-title":"Am J Ther"},{"key":"2022031223061444400_B33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2337\/diab.34.5.477","article-title":"Nonenzymatic glycation of fibronectin and alterations in the molecular association of cell matrix and basement membrane components in diabetes mellitus","volume":"34","author":"Tarsio","year":"1985","journal-title":"Diabetes"},{"key":"2022031223061444400_B34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2337\/diab.41.2.S49","article-title":"Structural and functional changes of laminin and type IV collagen after nonenzymatic glycation","volume":"41","author":"Charonis","year":"1992","journal-title":"Diabetes"},{"key":"2022031223061444400_B35","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1046\/j.1523-1755.2001.59780037.x","article-title":"3-deoxyglucosone and AGEs in uremic complications: inactivation of glutathione peroxidase by 3-deoxyglucosone","volume":"78","author":"Niwa","year":"2001","journal-title":"Kidney Int Suppl"},{"key":"2022031223061444400_B36","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.2337\/diabetes.51.8.2648","article-title":"Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin","volume":"51","author":"Christ","year":"2002","journal-title":"Diabetes"},{"key":"2022031223061444400_B37","doi-asserted-by":"crossref","first-page":"e11093","DOI":"10.1371\/journal.pone.0011093","article-title":"Precursor of advanced glycation end products mediates ER-stress-induced caspase-3 activation of human dermal fibroblasts through NAD(P)H oxidase 4","volume":"5","author":"Loughlin","year":"2010","journal-title":"PLoS ONE"},{"key":"2022031223061444400_B38","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2337\/diabetes.49.3.466","article-title":"Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats","volume":"49","author":"Sassy-Prigent","year":"2000","journal-title":"Diabetes"},{"key":"2022031223061444400_B39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.ki.5000014","article-title":"Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice","volume":"69","author":"Chow","year":"2006","journal-title":"Kidney Int"},{"key":"2022031223061444400_B40","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1681\/ASN.2004070612","article-title":"Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db\/db mice","volume":"16","author":"Chow","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2022031223061444400_B41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ndt\/gfi210","article-title":"Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes","volume":"21","author":"Gu","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2022031223061444400_B42","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1089\/ars.2007.1999","article-title":"Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway","volume":"10","author":"Guo","year":"2008","journal-title":"Antioxid Redox Signal"},{"key":"2022031223061444400_B43","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1681\/ASN.2005010062","article-title":"Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy","volume":"16","author":"Forbes","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2022031223061444400_B44","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2337\/diabetes.53.7.1813","article-title":"Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis","volume":"53","author":"Forbes","year":"2004","journal-title":"Diabetes"},{"key":"2022031223061444400_B45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00125-003-1256-8","article-title":"Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat","volume":"47","author":"Davis","year":"2004","journal-title":"Diabetologia"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/61\/8\/2105\/564565\/2105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/61\/8\/2105\/564565\/2105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:29:16Z","timestamp":1667406556000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/61\/8\/2105\/33852\/Alagebrium-Reduces-Glomerular-Fibrogenesis-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,17]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2012,7,17]]},"published-print":{"date-parts":[[2012,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db11-1546","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,17]]}}}